Business
Scancell Appoints Sath Nirmalananthan as CFO
Scancell Appoints Sath Nirmalananthan as CFO.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n 29 August 2023\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nScancell Appoints Sath Nirmalananthan as Chief Financial Officer\nKeith Green to retire as Director of Finance but to remain as Company Secretary\nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the appointment of Sath Nirmalananthan as Chief Financial Officer (CFO), with immediate effect.\n \nSath Nirmalananthan is an experienced finance professional with over 15 years experience across healthcare in FTSE and NASDAQ listed companies, investment banking and audit. Before joining Scancell, Sath was Chief Financial Officer for Europe, Middle-East and Africa at Prenetics, a leading genomics-driven health sciences company. Prior to that, Sath worked at Reckitt where he was Finance Director for Group Reporting and subsequently for eCommerce in Reckitt's Health Division. Sath has also held senior positions at BTG plc, a specialty pharmaceutical company, including Director of Group Reporting and Director of FP&A of interventional oncology. Earlier in his career, he was an equity research analyst in the healthcare team at Nomura and prior to that an auditor at KPMG. Sath earned a BSc in Pharmacology from King's College, London, UK and holds an ACA (ICAEW), Chartered Accountant qualification. Sath is also a Non-Executive member of the audit committee at The Institute of Cancer Research (ICR).\n \nProf Lindy Durrant, Chief Executive Officer of Scancell, commented: \"We are excited to have Sath join us as Chief Financial Officer. His financial acumen and extensive track record of building value in emerging biopharmaceutical companies will benefit Scancell in our next stage of evolution. I look forward to working with him closely as we continue to focus the clinical development of our two lead cancer vaccine assets, SCIB1 and Modi-1, whilst continuing to leverage the potential of our proprietary antibody platform through additional licensing and revenue generating opportunitie...